Kliniczny Szpital Wojewodzki Nr 2 Im. Sw. Jadwigi Krolowej W Rzeszowie

The department focuses on acute lymphoblastic leukemia, lymphoblastic lymphoma and myeloid leukemia in children, aiming to improve survival by testing novel immunotherapies and optimizing chemotherapy regimens.

• Targeted immunotherapy approaches
• Proteasome inhibition strategies
• Genetic risk‑adapted treatment
• Reduction of treatment‑related toxicities

Collaborative trials with the AIEOP‑BFM network enhance trial enrollment at Kliniczny Szpital Wojewodzki Nr 2.

Research addresses growth hormone deficiency, short stature due to Turner, Noonan or small‑for‑gestational‑age origins, and congenital adrenal hyperplasia, evaluating new hormone therapies and dosage regimens to support normal growth.

• Comparison of weekly versus daily growth hormone delivery
• Adrenal steroid suppression assessment
• Genetic diagnostics for growth failure
• Long‑term safety of hormone replacement

The II Klinika Pediatrii, Endokrynologii i Diabetologii Dzieciecej leads these pediatric endocrine studies.

Trials target obesity and its metabolic complications, including type 2 diabetes and early type 1 diabetes, testing agents that sustain weight loss and improve glycemic control in adolescents.

• Weight‑management drug efficacy
• Beta‑cell preservation in recent‑onset diabetes
• Maintenance of BMI after initial loss
• Metabolic risk reduction strategies

Studies incorporate the site’s expertise in pediatric metabolism and nutrition.

Investigations include patients with acute myocardial infarction and chronic heart failure, evaluating anti‑inflammatory agents, SGLT2 inhibitors, and novel biomarkers to lower cardiovascular events and improve quality of life.

• IL‑6 pathway blockade after myocardial infarction
• SGLT2 inhibitor impact on worsening heart failure
• Thrombolysis safety in anticoagulated stroke patients
• Biomarker‑guided therapeutic decisions

The ARTEMIS trial of ziltivekimab exemplifies the site’s cardiovascular research portfolio.

The center evaluates treatments for complicated urinary tract infection, acute pyelonephritis and other serious bacterial infections in children, focusing on safety, pharmacokinetics and resistance patterns.

• Safety of new IV antimicrobials in pediatrics
• Oral antibiotic pharmacokinetic profiling
• Management of neonatal respiratory infections
• Surveillance of antimicrobial resistance

Vabomere (meropenem‑vaborbactam) studies are conducted under the hospital’s infectious‑disease protocol.

Clinical work explores systemic lupus erythematosus and lupus nephritis, testing biologics such as anifrolumab and ianalumab to achieve renal remission and disease control.

• IL‑6 and interferon pathway inhibition
• B‑cell depletion strategies
• Complete renal response endpoints
• Long‑term safety of targeted therapies

The SRI‑4 outcome measure guides efficacy assessment in SLE trials.

Research includes patients with acute ischemic stroke, assessing reperfusion techniques, reversal agents for anticoagulation, and functional outcomes after treatment.

• Thrombolysis with rtPA in DOAC‑reversed patients
• Functional recovery measured by modified Rankin scale
• Safety of anticoagulant antidotes
• Imaging biomarkers for early prognosis

The STROACT study provides critical data on stroke management in anticoagulated populations.